# US 2025/0179000 A1 · Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0179000 A1
- Document ID: US20250179000A1
- Status: Published application
- Kind: A1
- Application number: 18/723,093
- Filed: 2022-12-22
- Published: 2025-06-05
- Earliest claimed: 2021-12-23
- Assignees: Sanford Burnham Prebys Medical Discovery Institute
- Applicants: Sanford Burnham Prebys Medical Discovery Institute
- Inventors: Nicholas David Peter COSFORD; Douglas J. SHEFFLER; Dhanya RAVEENDRA-PANICKAR
- Web page: https://patentgrep.com/patent/US20250179000A1

## CPC

- C07C 65/24: polycyclic
- A61P 25/00: Drugs for disorders of the nervous system
- C07C 65/28: having unsaturation outside the aromatic rings
- C07C 65/40: containing singly bound oxygen-containing groups
- C07C 217/22: by carbon atoms having at least two bonds to oxygen atoms
- C07C 229/66: the carbon skeleton being further substituted by doubly-bound oxygen atoms
- C07C 255/29: containing cyano groups and acylated amino groups bound to the carbon skeleton
- C07C 255/30: containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton
- C07C 271/16: to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C07C 311/17: to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 311/55: having sulfur atoms of the sulfonylurea groups bound to acyclic carbon atoms
- C07C 317/18: with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C 317/32: with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C 321/28: Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C 323/12: the carbon skeleton being acyclic and saturated
- C07C 323/16: the carbon skeleton containing six-membered aromatic rings
- C07C 323/18: having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C 323/20: with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07D 213/30: Oxygen atoms
- C07D 213/80: in position 3
- C07D 237/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 239/26: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 241/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 271/107: with two aryl or substituted aryl radicals attached in positions 2 and 5
- C07D 311/22: with oxygen or sulfur atoms directly attached in position 4
- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07C 2601/02: with a three-membered ring
- C07C 2601/16: the ring being unsaturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, having the structure of formula (I):
wherein:
R1 is substituted or unsubstituted C2-C6 alkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;
X1 is absent, —O—, —NR5—, —S—, —S(═O)—, or —S(═O)2—;
X2 is —O—, —NR6—, —S—, —S(═O)—, or —S(═O)2—;
R5 and R6 are each independently hydrogen, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —C(═O)R4, —S(═O)2R4, or —C(═O)OR3;
L1 is substituted C4 alkylene, substituted or unsubstituted C5-C10 alkylene, substituted or unsubstituted C2-C10 alkenylene, substituted or unsubstituted C2-C10 alkynylene, -L3-X3-L4-, or -L5-X4-L6-;
L3 and L4 are each independently substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C2-C6 alkenylene, or optionally substituted or unsubstituted C2-C6 alkynylene;
X3 is —C(R′)2—, —C(R9)═C(R9)—, —C≡C—, —O—, —NR7—, —S—, —S(═O)—, or —S(═O)2—;
L5 and L6 are each —C(D)2- and X4 is substituted or unsubstituted C1-C4 alkylene;
R7 is hydrogen, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —C(═O)R4, —S(═O)2R4, or —C(═O)OR3;
each R8 is independently D, halogen, —OH, substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C1-C6fluoroalkyl;
or two R8 are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted cycloalkyl or a substituted or unsubstituted heterocycloalkyl;
each R9 is independently hydrogen, D, halogen, —OH, substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C1-C6fluoroalkyl;
L2 is absent or C1-C6 alkylene;
Q is —C(═O)OH, —C(═O)OR4, —C(═O)NHOR3, —C(═O)NHCN, —C(═O)NR3R3, —C(═O)NHS(═O)2R4, —C(═O)R4, —S(═O)2NR3R3, —S(═O)2NHC(═O)R4, —NHC(═O)NHS(═O)2R4,
each R2 is independently halogen, nitro, —CN, —OH, —OR4, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, or substituted or unsubstituted cycloalkyl;
n is 0, 1, 2, 3, or 4;
Y is —OH, —OR4, halogen, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, or substituted or unsubstituted cycloalkyl;
Z is —OH, —OR4, halogen, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, or substituted or unsubstituted cycloalkyl;
each R3 is independently hydrogen, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
or two R3 taken together with the nitrogen to which they are attached to form a substituted or unsubstituted C2-C8heterocycloalkyl;
each R4 is independently substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted cycloalkyl substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: Y is —OH.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: Z is substituted or unsubstituted C1-C6alkyl.

### Claim 6 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt or solvate, wherein: Z is methyl.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: L2 is C1-C6 alkylene.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: L2 is absent.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: Q is —C(═O)OH, —C(═O)OR4, —C(═O)NHOR3, —C(═O)NR3R3, —C(═O)NHS(═O)2R4, —C(═O)R4, —S(═O)2NR3R3, —S(═O)2NHC(═O)R4,
and
wherein each R3 and R4 is independently hydrogen or substituted or unsubstituted C1-C6alkyl.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: Q is —C(═O)OH or —C(═O)OR4; and wherein R4 is methyl or ethyl.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is unsubstituted C2-C6 alkyl.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: each R2 is independently halogen, nitro, —CN, —OH, —OR4, substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C1-C6fluoroalkyl; and wherein R4 is substituted or unsubstituted C1-C6alkyl.

### Claim at position 17

-25. (canceled)

### Claim 26 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: X1 is —O—.

### Claim at position 19

-29. (canceled)

### Claim 30 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: X2 is —O—.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: L1 is substituted C4 alkylene, substituted or unsubstituted C5-C10 alkylene, substituted or unsubstituted C2-C10 alkenylene, or substituted or unsubstituted C2-C10 alkynylene.

### Claim at position 24

-51. (canceled)

### Claim 52 (depends on 1)

The compound of any claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound of Formula (I) has the structure of Formula (Ia), or a pharmaceutically acceptable salt, or solvate thereof:
wherein:
L3 and L4 are each independently C1-C4alkylene;
X3 is —C(R8)2, —C(R9)═C(R9)—, —C≡C—, —O—, —NR7—, —S—, —S(═O)—, or —S(═O)2—;
each R8 is independently D, halogen, —OH, substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C1-C6fluoroalkyl;
or two R8 are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted cycloalkyl or a substituted or unsubstituted heterocycloalkyl;
each R9 is independently hydrogen, D, halogen, —OH, substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C1-C6fluoroalkyl.

### Claim at position 26

53-126. (canceled)

### Claim 127

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 128 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.

### Claim 129

(canceled)

### Claim 130

(canceled)

### Claim 131 (depends on 1)

A method of treating a central nervous disorder (CNS) disorder, the method comprising the step of administering to a subject in need thereof, an effective amount of the compound of claim 1, thereby treating the disorder.

### Claim at position 32

-138. (canceled)

### Claim 139 (depends on 1)

A method of treating substance abuse, the method comprising the step of administering to a subject in need thereof, an effective amount of the compound of claim 1, wherein the effective amount is sufficient to diminish, inhibit or eliminate desire for and/or consumption of the substance in the subject.

### Claim 140 (depends on 139)

The method of claim 139, wherein the substance is nicotine, alcohol, opiates, amphetamines, methamphetamines, or cocaine.

### Claim 141 (depends on 1)

A method for treating an addictive disorder, the method comprising the steps of: a) administering to a subject in need thereof, an effective amount of the compound of claim 1, during a first time period, wherein the first time period is a time period wherein the subject expects to be in an environment wherein, or exposed to stimuli in the presence of which, the subject habitually uses an addictive substance; and b) administering an effective amount of the compound of claim 1 during a second time period, wherein the second time period is a time period wherein the subject is suffering from withdrawal.
